Astel­las sub­sidiary to part­ner with Pitts­burgh up­start in search for 'un­drug­gable' pro­teins

As Astel­las con­tin­ues its dri­ve to build out its gene ther­a­py port­fo­lio and ca­pa­bil­i­ties, a sub­sidiary of the Japan­ese phar­ma com­pa­ny has en­tered in­to a col­lab­o­ra­tion with a lit­tle-known Pitts­burgh biotech.

Astel­las-owned Mi­to­bridge and Gener­ian Phar­ma­ceu­ti­cals an­nounced on Wednes­day that they will work to­geth­er in a new deal for “un­drug­gable” pro­tein tar­gets. Gener­ian will net an undis­closed up­front pay­ment and could get up to $180 mil­lion in mile­stones, should any­thing from its plat­form prove suc­cess­ful, as well as sin­gle-dig­it roy­al­ties on glob­al net sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER